An interventional study of Opioid Phase in Chronic Pain and Opioid Use, sponsored by Duke University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Duke University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Chronic Pain by Duke University — 5 open to participants now, 5 under way, none of them phase 3. Chronic Pain · Duke University.
Among the 19 studies in Chronic Pain by Duke University, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2023, is one of 14 with no phase, and was the 13th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →5 of the 19 studies in Chronic Pain by Duke University are open now, in 1 country. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 21–65
Duke University · Sites in United States
Ages 21+
Duke University · Sites in United States
Ages 15–40
Duke University · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 99 across the 16 interventional studies, 81 across the 3 observational. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
3 of the studies in Chronic Pain by Duke University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07525063Duke UniversityPain & Reward Neuromodulation of CNS Circuits | 2026-12 |
| NCT05905419Duke UniversityNeuroimaging of Opioid Phase (OPAL) | 2027-06-30 |
| NCT06747871Duke UniversityOpioids, Low Nicotine Cigarettes, and Chronic Pain | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies in Chronic Pain by Duke University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare activity in the brains of female adults with chronic pain and/or opioid use, and healthy female adults that may help to develop new and targeted treatments for adults with chronic pain and alternatives to opioid therapy.
The objective of the study is to determine differences in neurophysiology and behavior during different phases of opioid use in patients. Study activities will include neuroimaging (MRI and fMRI), behavioral tasks, sensory testing, blood draws, and questionnaires. The neuroimaging data will be analyzed using specialized software; data from questionnaires, sensory testing, and behavioral task performance will be analyzed using standard statistical software. Risks and safety concerns include standard, minimal risks associated with MRI scans, sensory testing, blood draws, and confidentiality.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria for Individuals with Chronic Pain:
Exclusion Criteria (for both groups):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Opioid taking participants will undergo two study visits, one for each opioid phase ("peak" or "trough")
Other: Opioid Phase
Participants with chronic pain who are not taking opioids will undergo one study visit
Healthy female participants who are not taking opioids will undergo one study visit
Opioid-taking patients are assigned to take their prescribed opioid medication before ("peak" opioid phase) during 1 scan and after ("trough" opioid phase) during the other MRI scan
Characterize brain fMRI-based activity related to neurobiological consequences of opioid therapy
Compare brain fMRI-based response to reward stimuli during a monetary incentive delay (MID) task and functional connectivity of brain reward circuitry during resting state.
Time frame: During study visits up to 4 weeks apart
Characterize spinal cord fMRI-based activity related to neurobiological consequences of opioid therapy
Compare spinal cord fMRI-based response and resting-state functional connectivity.
Time frame: During study visits up to 4 weeks apart
Plan to share: No
Started Jun 2023 (actual). Primary completion is estimated for Jun 2027, 48 months after the start.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 48 months is above that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.